One resident has been receiving two different anti-seizure medications twice daily since early 2024, yet the facility never created a care plan addressing the seizure disorder or monitoring needs for these drugs.
The resident, identified as R2 in inspection records, takes Lamotrigine 200 milligrams twice daily and Phenytoin Sodium 200 milligrams twice daily. Medical records show an active diagnosis of epileptic seizures related to external causes. Despite this serious neurological condition requiring careful medication management, no care plan existed to establish treatment goals or monitoring protocols.
Director of Nursing V2 acknowledged the oversight when confronted by inspectors on September 18. The director confirmed that both the seizure disorder and seizure medications were missing from the resident's care plan entirely.
"V2 is responsible for updating the care plans and V2 will update R2's care plan," the director told inspectors, accepting personal responsibility for the deficiency.
A second resident faced similar gaps in care planning around opioid use. This resident, R3, has been taking Tramadol 50 milligrams daily since April 2023 without any care plan addressing the opioid medication or its associated risks.
Tramadol carries significant monitoring requirements, particularly for elderly nursing home residents who face increased risks of constipation, falls, and cognitive impairment from opioid use. The facility's care plan included none of these considerations.
The director confirmed to inspectors that the resident's care plan failed to address Tramadol use, necessary interventions, or constipation risks that commonly accompany opioid therapy in elderly patients.
Care plans serve as roadmaps for nursing home staff, outlining specific problems residents face, goals for their treatment, and step-by-step interventions to achieve those goals. Federal regulations require facilities to develop comprehensive care plans that address all of a resident's needs, including medication management and monitoring.
The inspection focused specifically on medication-related care planning after reviewing a sample of three residents. Two of the three had significant gaps in their care plans despite taking medications requiring careful oversight.
For the seizure patient, the absence of a care plan meant no formal protocols existed for monitoring medication effectiveness, watching for side effects, or responding to breakthrough seizures. Anti-seizure medications like Lamotrigine and Phenytoin require regular blood level monitoring and careful observation for adverse reactions.
The opioid patient faced different but equally serious risks without proper care planning. Tramadol can cause dangerous interactions with other medications commonly prescribed to elderly residents. It also increases fall risk and can lead to severe constipation requiring preventive interventions.
Both medications have been administered for months without the benefit of structured care planning. The seizure medications began in February 2024 for Lamotrigine and May 2025 for Phenytoin Sodium. The Tramadol prescription dates back more than two years to April 2023.
The inspection occurred in response to a complaint, though the specific nature of the complaint was not detailed in available records. Inspectors classified the violations as causing "minimal harm or potential for actual harm" affecting "few" residents.
The facility's medication administration records showed consistent daily dosing of the medications, indicating staff were following prescription orders. However, without care plans, no systematic approach existed to evaluate whether the medications were achieving their intended therapeutic goals or causing harmful side effects.
The director's admission of responsibility during the inspection suggests awareness of the care planning requirements. However, the extended periods during which residents received medications without proper care plans raises questions about the facility's systematic approach to comprehensive care planning.
Federal regulations require nursing homes to assess residents' needs and develop individualized care plans within specific timeframes. These plans must be updated regularly and revised when residents' conditions change or new medications are prescribed.
The violations occurred at a 60-bed facility that has operated in the small central Illinois community for years. Flanagan, located in Livingston County, has a population of fewer than 1,200 residents.
Both affected residents continue to receive their medications while the facility works to develop appropriate care plans addressing their complex medical needs and medication monitoring requirements.
Full Inspection Report
The details above represent a summary of key findings. View the complete inspection report for Flanagan Rehabilitation & Hcc from 2025-09-18 including all violations, facility responses, and corrective action plans.
Additional Resources
- View all inspection reports for Flanagan Rehabilitation & Hcc
- Browse all IL nursing home inspections